办公室血压和肥胖症在X链接低酸血症的儿童
Ineke Böckmann1, Maren Leifheit-Nestler1, Mirko Rehberg2
1Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Calcified tissue international
|March 28, 2025
概括
患有X链接低血症 (XLH) 的儿童经常患有高血压和肥胖. 增加的BMI与儿科XLH患者的高血压有关,无论治疗类型如何.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 腎臟病學 (nephrology) 是一種醫學.
- 遗传学 是一个遗传学.
背景情况:
- 链接到X的低血症 (XLH) 是一种常见的遗传性疾病,会导致恶心.
- XLH与肥胖的风险增加有关,可能会影响心血管健康.
- 关于儿科XLH患者血压的现有数据是不确定的.
研究的目的:
- 为了评估XLH儿童的血压水平.
- 研究儿科XLH患者的血压及其决定因素 (包括BMI和治疗方式) 之间的关系.
主要方法:
- 在德国和瑞士进行了一项前性的多中心观察研究.
- 128名儿科XLH患者被随访了平均2年,每年对办公室血压和BMI进行测量.
- 斯皮尔曼相关性分析被用来识别血压的预测因素.
主要成果:
- 与健康儿童相比,XLH患者的血压中位数增加了静缩 (0.75z-score) 和静缩 (0.32z-score),体重指数 (BMI) 增加了 (0.72z-score).
- 肥胖 (9.8%),高血压 (26.2%) 和高正常血压 (22.9%) 的患病率在XLH队列中明显高.
- 升高的静脉和腹血压与BMI有显著的正相关性,不依赖于治疗布罗苏马布或酸盐/维生素D补充剂.
结论:
- 患有XLH的儿科患者经常出现办公室血压升高.
- 增加的BMI是XLH儿童高血压的重要相关因子.
- 这些发现强调了监测血压和控制体重在儿科XLH治疗中的重要性.
相关概念视频
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...


